Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Existing clinical evidence indicates that many tyrosine kinase inhibitors (TKIs) are associated with idiosyncratic hepatotoxicity. TKIs possess risk factors for developing drug-induced liver injury such as their high daily dose, being substrates of P450 enzyme and being involved in significant hepatic metabolism. Several successful strategies to overcome TKI-induced hepatotoxicity include: switching to an alternative TKI with a similar mechanism of action, using an alternative dose and introduction of corticosteroids for treatment and prevention of hepatotoxicity. AREAS COVERED: This review highlights the formation of reactive metabolites and how this leads to toxicity, as well as the current clinical management of TKI-induced hepatotoxicity. EXPERT OPINION: Numerous events need to occur in an individual patient before converging into an idiosyncratic hepatotoxicity episode. Of these, the formation of a reactive intermediate through metabolism appears to be the prerequisite. This critical event involves an intricate chemico-biological interaction where, on one hand, drug-specific characteristics create the propensity for occurrence and, on the other hand, patient risk factors determine the individuality of response. With improved understanding of the mechanisms leading to adverse events, several strategies are being adopted to prevent and treat TKI-induced hepatotoxicity. However, further evidence is required before they can be recommended to larger populations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lee, W. M. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021844 · Cited by 1,594
N-acetyl-p-benzoquinone imine: a cytochrome P-450-mediated oxidation product of acetaminophen.
Dahlin, D. C., Miwa, G. T., Lu, A. Y., & Nelson, S. D. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.5.1327 · Cited by 1,078
Idiosyncratic drug hepatotoxicity
Kaplowitz, N. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1750 · Cited by 1,054
Central role of mitochondria in drug-induced liver injury
Pessayre, D., Fromenty, B., Berson, A., Robin, M.-A., Lettéron, P., Moreau, R., & Mansouri, A. (2012) · Drug Metabolism Reviews · doi:10.3109/03602532.2011.604086 · Cited by 277
Cited by
Stine, J. G., & Lewis, J. H. (2016) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/17474124.2016.1127756 · Cited by 104
An integrative machine learning approach for prediction of toxicity-related drug safety
Lysenko, A., Sharma, A., Boroevich, K. A., & Tsunoda, T. (2018) · Life Science Alliance · doi:10.26508/lsa.201800098 · Cited by 88
Recent advances in metabolism and toxicity of tyrosine kinase inhibitors
Zhao, Q., Wu, Z. E., Li, B., & Li, F. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108256 · Cited by 57
Hepatotoxicity of FDA-approved small molecule kinase inhibitors
Jiang, H., Jin, Y., Yan, H., Xu, Z., Yang, B., He, Q., & Luo, P. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1867104 · Cited by 13
Xie, L., Xu, J., Guo, W., Wang, Z., Yao, Y., Li, J., Lin, J., Xiao, J., Yu, X., Zhang, W., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.696865 · Cited by 9
“AE management: Consult with hepatologists for more advice and stopping apatinib (for grade ≥ 3); Corticosteroids are frequently administered to patients with certain DILI (for grade ≥ 3); Cholestyramine can be administered to patients with acute liver injury (for grade ≥ 2); When acute liver failure happens, consideri…”
BackgroundInfluential
Metadata
- Authors
- Teo, Y. L., Ho, H. K., & Chan, A.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa Healthcare
- Published
- 2014-11-15
- Volume
- 11
- Issue
- 2
- Pages
- 231-242
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2008271829
- Cited by
- 64
- References
- 4
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. https://app.cochat.ai/papers/10.1517/17425255.2015.983075
- The paper
- Teo, Y. L., Ho, H. K., & Chan, A. (2015). Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2015.983075
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.